Wall Street analysts expect that TG Therapeutics, Inc (NASDAQ:TGTX) will report sales of $40,000.00 for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for TG Therapeutics’ earnings. TG Therapeutics also posted sales of $40,000.00 in the same quarter last year. The company is expected to announce its next quarterly earnings report on Wednesday, August 8th.
On average, analysts expect that TG Therapeutics will report full year sales of $150,000.00 for the current fiscal year. For the next year, analysts anticipate that the company will post sales of $15.47 million per share, with estimates ranging from $9.84 million to $19.00 million. Zacks’ sales averages are an average based on a survey of research firms that cover TG Therapeutics.
TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Tuesday, May 8th. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.15). The company had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.04 million. TG Therapeutics had a negative net margin of 87,025.00% and a negative return on equity of 170.83%.
Several equities analysts have recently issued reports on TGTX shares. BidaskClub upgraded TG Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, March 6th. Zacks Investment Research upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 16th. Raymond James restated a “buy” rating on shares of TG Therapeutics in a research note on Thursday, April 19th. B. Riley restated a “buy” rating and set a $27.00 target price (up previously from $21.50) on shares of TG Therapeutics in a research note on Friday, March 9th. Finally, ValuEngine upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $24.60.
Shares of TG Therapeutics opened at $14.05 on Friday, according to Marketbeat.com. The stock has a market capitalization of $1.06 billion, a PE ratio of -7.36 and a beta of 1.21. TG Therapeutics has a 1 year low of $7.25 and a 1 year high of $17.35.
A number of hedge funds have recently bought and sold shares of the stock. Millennium Management LLC purchased a new stake in TG Therapeutics during the first quarter worth approximately $5,538,000. Highland Capital Management LP purchased a new stake in TG Therapeutics during the first quarter worth approximately $6,595,000. Cubist Systematic Strategies LLC purchased a new stake in TG Therapeutics during the first quarter worth approximately $176,000. Point72 Asset Management L.P. purchased a new stake in TG Therapeutics during the first quarter worth approximately $8,574,000. Finally, venBio Select Advisor LLC lifted its stake in TG Therapeutics by 58.7% during the first quarter. venBio Select Advisor LLC now owns 5,229,619 shares of the biopharmaceutical company’s stock worth $74,261,000 after purchasing an additional 1,935,156 shares during the last quarter. Hedge funds and other institutional investors own 47.35% of the company’s stock.
About TG Therapeutics
TG Therapeutics, Inc, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.